Kidney Cancer Clinical Trial

A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

Summary

This is a Phase 1b, open-label, multicenter, safety, tolerability and efficacy study of HC-7366 in combination with belzutifan (WELIREG™). This is a multipart study that consists of a HC-7366 monotherapy cohort, a combination dose escalation, and a combination dose expansion. Approximately 80 patients will be enrolled in this study (up to 20 patients will be enrolled into the HC-7366 monotherapy cohort, up to 30 patients into the combination dose escalation, and up to 30 patients into the combination dose expansion). The primary purpose of this study is to determine the maximum tolerated dose of HC-7366 in combination with belzutifan in patients with locally advanced (inoperable) or metastatic RCC with predominantly clear cell histology, irrespective of VHL gene mutation status.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Has diagnosis of locally advanced (inoperable) or metastatic RCC with a predominant clear cell component
Be age 18 years or older (male or female) at the time of consent

Study is for people with:

Kidney Cancer

Phase:

Phase 1

Estimated Enrollment:

80

Study ID:

NCT06234605

Recruitment Status:

Recruiting

Sponsor:

HiberCell, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 11 Locations for this study

See Locations Near You

University of California San Diego Moores Cancer Center
La Jolla California, 92093, United States More Info
Karen Cuervo
Contact
[email protected]
Cedars-Sinai Medical Center
Los Angeles California, 90048, United States More Info
Linda Ford
Contact
[email protected]
Rocky Mountain Cancer Centers, LLP
Lone Tree Colorado, 80124, United States More Info
Bobbie Donnachaidh
Contact
[email protected]
Jennifer Hege
Contact
[email protected]
HealthPartners Cancer Research Center
Saint Paul Minnesota, 55101, United States More Info
Octav Pacurar
Contact
[email protected]
Washington University School of Medicine
Saint Louis Missouri, 63110, United States More Info
Joel Picus
Contact
Memorial Sloan Kettering Cancer Center
New York New York, 10065, United States More Info
Rachel Jacobi
Contact
[email protected]
University Hospitals Cleveland Medical Center
Cleveland Ohio, 44106, United States More Info
Kathryn Helminiak
Contact
[email protected]
Cleveland Clinic
Cleveland Ohio, 44195, United States More Info
David Lynn
Contact
[email protected]
Providence Cancer Institute
Portland Oregon, 97213, United States More Info
Katrina Herz
Contact
[email protected]
SCRI Oncology Partners
Nashville Tennessee, 37203, United States More Info
Emma Brennan
Contact
[email protected]
Lauren King
Contact
[email protected]
Texas Oncology
Dallas Texas, 75246, United States More Info
Lisa Jones
Contact
[email protected]

How clear is this clinincal trial information?

Study is for people with:

Kidney Cancer

Phase:

Phase 1

Estimated Enrollment:

80

Study ID:

NCT06234605

Recruitment Status:

Recruiting

Sponsor:


HiberCell, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider